Needham & Company LLC Cuts Gamida Cell (NASDAQ:GMDA) Price Target to $8.00

Gamida Cell (NASDAQ:GMDAGet Rating) had its price objective reduced by Needham & Company LLC from $9.00 to $8.00 in a research report sent to investors on Tuesday, MarketBeat reports. They currently have a buy rating on the stock.

A number of other analysts have also issued reports on GMDA. Oppenheimer decreased their price objective on Gamida Cell from $15.00 to $10.00 and set an outperform rating on the stock in a research note on Tuesday, November 15th. Piper Sandler reduced their price objective on Gamida Cell from $8.00 to $7.00 and set an overweight rating on the stock in a research report on Monday, October 3rd. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of Buy and an average price target of $12.80.

Gamida Cell Trading Down 12.9 %

Shares of GMDA stock opened at $1.55 on Tuesday. The company has a market cap of $91.76 million, a P/E ratio of -1.21 and a beta of 1.63. Gamida Cell has a fifty-two week low of $1.32 and a fifty-two week high of $4.72. The stock has a 50 day simple moving average of $1.83 and a two-hundred day simple moving average of $2.09. The company has a debt-to-equity ratio of 5.31, a quick ratio of 2.76 and a current ratio of 2.76.

Gamida Cell (NASDAQ:GMDAGet Rating) last released its quarterly earnings data on Monday, November 14th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.02. Research analysts forecast that Gamida Cell will post -1.18 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GMDA. Virtu Financial LLC bought a new position in Gamida Cell during the 2nd quarter valued at approximately $36,000. Levin Capital Strategies L.P. bought a new stake in shares of Gamida Cell in the 3rd quarter worth $40,000. Cubist Systematic Strategies LLC bought a new stake in shares of Gamida Cell in the 2nd quarter worth $42,000. OLD National Bancorp IN bought a new stake in shares of Gamida Cell in the 2nd quarter worth $57,000. Finally, Stock Yards Bank & Trust Co. bought a new stake in shares of Gamida Cell in the 2nd quarter worth $62,000. Institutional investors own 41.27% of the company’s stock.

Gamida Cell Company Profile

(Get Rating)

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia.

Featured Articles

Analyst Recommendations for Gamida Cell (NASDAQ:GMDA)

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.